AxoGen, Inc.

AxoGen, Inc.

AXGN

$43.32

Updated: 24/09/2026, 10:09:45

Market Cap
$2.33B
Sector
Healthcare
Industry
Medical - Devices
Country
US
Stock valuation chart
One-year closing share-price history for AXGN
Company Profile

AxoGen, Inc., along with its subsidiaries, specializes in creating and distributing medical devices for the surgical repair of injured or severed peripheral nerves. Their comprehensive product portfolio offers several innovative solutions. The Avance Nerve Graft is a ready-to-use, biologically active human nerve allograft designed to bridge gaps in severed nerves. This avoids the need for a second surgical site for tissue donation, thereby eliminating associated complications. For facilitating the gentle reconnection of severed peripheral nerves, the company offers the AxoGuard Nerve Connector, an extracellular matrix (ECM) derived from porcine submucosa. This same porcine submucosa ECM forms the basis of the AxoGuard Nerve Protector, which is utilized to encase and safeguard damaged peripheral nerves, supporting their reconstruction and preventing unwanted adhesions from surrounding soft tissues. Another ECM product, the AxoGuard Nerve Cap, isolates the nerve end from its environment to help mitigate the formation of painful neuromas. Furthermore, AxoGen provides the Avive Soft Tissue Membrane, a processed human umbilical cord membrane that functions as an absorbable covering for soft tissues, used to separate tissues within the surgical area. An additional tool available is the AxoTouch two-point discriminator, used for evaluating the density of nerve innervation on the skin's surface. These products are supplied to hospitals, surgery centers, and military medical facilities, catering to plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen's market reach extends across the United States, Canada, Germany, the United Kingdom, other European nations, South Korea, and internationally. The company's main operations are situated in Alachua, Florida.

USD
NASDAQ
CEO: Michael D. Dale
Employees: 622
https://www.axogeninc.com
Asset Summaries
Latest generated summaries for AXGN

No summaries found.

Detailed business
Structured knowledge from the latest official annual filing.
No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.
Full company information
Latest profile, trading, valuation, and identifier data stored for AXGN.
Share price
$43.32
Market cap
$2.33B
Exchange
NASDAQ
Currency
USD
CEO
Michael D. Dale
Employees
622
IPO date
17/12/1986
Beta
1.163
Last dividend
$0.00
Day range
$43.25 – $44.84
52-week range
$15.27 – $52.91
1-day performance
-2.74%
1-year performance
183.69%
Current drawdown (1Y)
-18.13%
CIK
0000805928
CUSIP
05463X106
ISIN
US05463X1063
Created
07/12/2025, 02:53:23
Last update
24/09/2026, 10:09:45

Track AxoGen, Inc. with an AI analyst

See which prediction-market events move AXGN, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.